BIOQUAL, Inc. : BIOQUAL Presents Financial Results for Fiscal Year 2013
October 29, 2013 at 07:17 pm IST
By
Share
BIOQUAL, Inc. (Pinksheets: BIOQ):
2013
2012
Revenue
$
20,204,308
$
22,667,149
(Loss) Income Before Income Tax
$
(107,016
)
$
362,199
Net (Loss) Income
$
(87,244
)
$
213,971
Basic (Loss) Earnings per Share of Common Stock
$
(.10
)
$
.24
Diluted (Loss) Earnings per Share of Common Stock
$
(.10
)
$
.24
Weighted Average Number of Shares Outstanding For Basic Earnings
894,934
895,994
Weighted Average Number of Shares Outstanding For Diluted Earnings
894,934
895,994
In view of current considerations, the Board of Directors determined not
to declare a dividend for Fiscal Year 2013.
Statements herein that are not descriptions of historical facts are
forward-looking and subject to risk and uncertainties. Actual results
could differ materially from those currently anticipated due to a number
of factors including risks relating to the ability to continue to extend
current government contracts and obtain new contracts; the actual cost
incurred in performing its contracts; uncertainties relating to clinical
trials; dependence on third parties; and future capital needs.
BIOQUAL, Inc. Mark G. Lewis, Ph.D., CEO, 301-251-2801 www.bioqual.com
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
By 